Inventurus Knowledge Solutions Limited – Investor Presentation Summary

Key Operational Highlights

  • Number of healthcare organizations served: 600+ in Q1 FY27, compared to 650+ in Q1 FY26.
  • Total employees: 12,889 as of June 30, 2026, with 1,902 clinically trained staff.
  • Technology focused employees: 565, sales and marketing employees: 57.
  • Total Addressable Market (TAM): US$260 billion for CY2023, with outsourced market at US$34 billion, growing at 8% and 12% CAGR respectively from 2023-2028E.
  • US healthcare expenditure: US$5 trillion in CY2024.
  • 85%+ revenues from repeat customers.
  • Top 10 clients average vintage: 5.76 years, top 5 clients: 7.41 years as of March 31, 2026.

Key drivers of operational performance: Emphasis on AI-driven workflows, platform integration, and cross-selling initiatives.

Segment-wise Performance: Not specified.

Financial Highlights

  • Revenue: INR 8,936 million for Q1 FY27, up 20.7% YoY from INR 7,401 million in Q1 FY26.
  • EBITDA excluding ESOP: INR 3,167 million, margin of 35.4%, up 28.4% YoY.
  • EBITDA including ESOP: INR 2,949 million, margin of 33.0%, up 24.0% YoY.
  • Profit before tax: INR 2,563 million, up 31.5% YoY.
  • Profit after tax: INR 1,937 million, margin of 21.7%, up 27.8% YoY.
  • Adjusted PAT (excluding amortization of intangible assets): INR 2,153 million, margin of 24.1%, up 28.0% YoY.
  • QoQ comparison: Revenue up 4.2% from Q4 FY26 INR 8,577 million, EBITDA down 1.8%, PAT down 5.9%.
  • Drivers of financial performance: Revenue growth and operational efficiencies, though specific drivers not detailed.
  • Comparison to market estimates: Not provided.
  • Key Risks: Not disclosed.

Geographical Revenue Split: Not specified.

Balance Sheet Snapshot

  • Free Cash Flow Yield: 89.9% for Q1 FY27, compared to 84.5% in Q1 FY26.
  • Other balance sheet metrics not provided.

Financial Health Insights: Strong cash flow generation indicated by high FCF Yield.

Capex & Cash Flow Health

  • Capital Expenditure: Not specified.
  • Free Cash Flow: Implied by FCF Yield, but not quantified.
  • Operating Cash Flow: Not specified.
  • Net Debt Movement: Not disclosed.
  • Investment Rationale: Focus on AI and platform integration, capacity expansion, and technology upgrades as per strategic pillars.

Strategic & R&D Initiatives

  • Five strategic pillars: Proprietary AI models, integrated systems, growth levers, margin optimization, culture and leadership.
  • Investments in AI training with 5MM+ longitudinal records, proprietary SLMs, explainable AI, human-in-the-loop workflows.
  • API integration with EHRs, cross-selling in installed base, and operating model transformation.
  • Expected impact on growth: Enhanced platform capabilities and market expansion.
  • Strategic Rationale: Expanding into high-growth markets, reducing operational costs, and leveraging synergies.

Industry Trends & Business Environment

  • Macro/Industry Trends: TAM for healthcare outsourcing growing at 12% CAGR 2023-2028E, US healthcare expenditure at US$5 trillion in 2024.
  • Impact on Company: Positions IKS Health to capture growth in outsourced market, though specific impacts not detailed.

Management Commentary & Growth Outlook

  • Strategic Outlook: "Sustained EBITDA expansion without significant dilution of Equity."
  • FY Guidance: Not explicitly provided, but medium-term outlook mentioned without details.
  • Market Share Targets: Not specified.
  • Risks and Opportunities: Not detailed.

Additional Information

  • Awards and Recognition: Best CFO & Finance Strategy Excellence Awards 2026, US Patent for Engagement Learning Engine, 2026 Dallas-Fort Worth Titan 100, AMGA Distinguished Corporate Partner Award 2026, FE HR Awards 2026.
  • Client Examples: Premier California Health System for clinical data migration, National Musculoskeletal Leader for RCM modernization, StrideCare for RCM services expansion, Advocate Health for RCM and coding expansion.